Top

Nuclear Medicine and Molecular Imaging

Published in:

07-03-2023 | Dementia | Original Article

Optimal Protocol and Clinical Usefulness of ¹²³I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases

Author: In Kook Chun

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2023

Abstract

Purpose

¹²³I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy was a useful imaging modality for the diagnosis of Parkinson’s disease, but its diagnostic performances were variably reported. This retrospective study compared the diagnostic performances and investigated the optimal imaging protocol of ¹²³I-MIBG cardiac scintigraphy at various imaging time points in patients suspected of Parkinson’s disease in clinical practice.

Methods

In patients suspected of Parkinson’s disease, clinical records, autonomic function tests, and ¹²³I-MIBG cardiac scintigraphy were retrospectively reviewed. Semi-quantitative parameters such as heart-to-mediastinum ratio (HMR) and washout rate (WR) were calculated and compared at 15 min, 1 h, 2 h, 3 h, and 4 h post-injection (p.i.). of ¹²³I-MIBG cardiac scintigraphy. Group A consisted of Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and dementia with Lewy body (DLB), and group B consisted of non-Parkinson’s diseases such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), drug-induced parkinsonism (DIP), essential tremor (ET), Parkinson-plus syndrome (PPS), and unspecified secondary parkinsonism (NA). The diagnostic performances of HMR and WR were compared for differentiation of group A from group B, and their clinical usefulness and optimal imaging time points were explored.

Results

Seventy-eight patients were included in group A (67 PD, 7 PDD, 4 DLB), and 18 patients were included in group B (5 MSA, 3 PSP, 2 DIP, 2 ET, 1 PPS, and 1 NA). Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value of HMR and WR were maximized at 4 h p.i., (82.1%, 85.7%, 82.6%, 97.0%, and 46.2%; cutoff threshold < 1.717; area under curve 0.8086) and at the time interval between 1 and 4 h p.i. (65.4%, 85.7%, 68.5%, 96.2%, and 30.8%; cutoff threshold > 24.1%; area under curve 0.8246), respectively, and PPVs of both HMR and WR persistently showed greater than 92.7% at earlier time points and shorter time intervals.

Conclusion

This study reassured that 4-h-delayed imaging is recommended for the best diagnostic performances in ¹²³I-MIBG cardiac scintigraphy. Although it showed suboptimal diagnostic performances to differentiate PD, PDD, and DLB from non-Parkinson’s diseases, it can be useful as an auxiliary measure for the differential diagnosis in usual clinical practice.

Available only for authorised users

Iheagwam FN, Etefia SI. Recent advances on the management of Parkinson’s disease: a review. Int Res J Med Sci. 2019;1(1):1–11.

Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5.PubMedCrossRef

Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med. 2016;16(4):371–5.CrossRef

Park KJ, Lee H, Kim HA, Kang SY, Kim BJ, Nam TS, et al. Guidelines for autonomic function test. J Pain Auton Disord. 2013;2(2):56–65.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS Clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.PubMedCrossRef

Flotats A, Carrió I, Agostini D, Guludec DL, Marcassa C, el al. Proposal for standardization of ¹²³I-metaiodobenzylguadinine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRef

Da Rocha ET, Alves WEFM, Verschure DO, Verberne HJ. The use of cardiac ¹²³I-mIBG scintigraphy in clinical practice: the necessity to standardize! Int J Cardiovasc Sci. 2017;30(6):533–41.

Verschure DO, Nakajima K, Jacobson AF, Verberne HJ. 40 years anniversary of cardiac ¹²³I-mIBG imaging: state of the heart. Curr Cardiovasc Imaging Rep. 2021;14:5.CrossRef

Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22(2):129–32.PubMed

10.

Dae MW, William O’connell J, Botvinick EH, Ahearn T, Yee E, Huberty JP, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989;79(3):634–44.PubMedCrossRef

11.

Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy. Am Heart J. 1993;126:390–8.PubMedCrossRef

12.

De Marco T, Dae M, MSF Y-g, Kumar S, Sudhir K, Keith F, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol. 1995;25(4):927–31.PubMedCrossRef

13.

Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36(6):969–74.PubMed

14.

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40(6):917–23.PubMed

15.

Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac ¹²³I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86(6):656–60.PubMedPubMedCentralCrossRef

16.

Kioka H, Yamada T, Mine T, Morita T, Tsukamoto Y, Tamaki S, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93(10):1213–8.PubMedPubMedCentralCrossRef

17.

Lemery R, Ben-Haim S, Wells G, Ruddy TD. I-123-Metaiodobenzylguanidine imaging in patients with atrial fibrillation undergoing cardiac mapping and ablation of autonomic ganglia. Heart Rhythm. 2017;14(1):128–32.PubMedCrossRef

18.

Clements IP, Kelkar AA, Garcia EV, Butler J, Chen J, Folks R, et al. Prognostic significance of ¹²³I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. Eur Heart J Cardiovasc Imaging. 2016;17(4):384–90.PubMedCrossRef

19.

Dimitriu-Leen AC, Gimelli A, Al Younis I, Veltman CE, Verberne HJ, Wolterbeek R, et al. The impact of acquisition time of planar cardiac ¹²³I-MIBG imaging on the late heart to mediastinum ratio. Eur J Nucl Med Mol Imaging. 2016;43(2):326–32.PubMedCrossRef

20.

Travin MI, Matsunari I, Thomas GS, Nakajima K, Yoshinaga K. How do we establish cardiac sympathetic nervous system imaging with ¹²³I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. J Nucl Cardiol. 2019;26(4):1434–51.PubMedCrossRef

21.

Sazonova SI, Atabekov TA, Batalov RE, Mishkina AI, Varlamova JV, Zavadovsky KV, et al. Prediction of appropriate ICD therapy in patients with ischemic heart failure. J Nucl Cardiol. 2022;29(2):680–91.PubMedCrossRef

22.

Seo M, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, et al. Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute Heart Failure Registry (OPAR). Eur Heart J Cardiovasc Imaging. 2021;22(1):58–66.PubMedCrossRef

23.

Kayama K, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, et al. Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the co-morbid burden in acute decompensated heart failure. ESC Heart Fail. 2021;8(2):1167–77.PubMedPubMedCentralCrossRef

24.

Satoh A, Serita T, Seto M, Tornita U, Satoh H, Iwanaga K, et al. Loss of ¹²³I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999;40(3):371–5.PubMed

25.

Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155(1):60–7.PubMedCrossRef

26.

Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H. ¹²³I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev. 2016;30:122–33.PubMedCrossRef

27.

Taki J, Nakajima K, Hwang E, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in PD without autonomic failure is heart selective and disease specific. Eur J Nucl Med. 2000;27(5):566–73.PubMedCrossRef

28.

Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001;11(6):351–5.PubMedCrossRef

29.

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76(2):249–51.PubMedPubMedCentralCrossRef

30.

Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, Hosokawa R, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol. 2009;16(2):174–82.PubMedCrossRef

31.

Kikuchi A, Baba T, Hasegawa T, Sugeno N, Konno M, Takeda A. Differentiating Parkinson’s disease from multiple system atrophy by [¹²³I]meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord. 2011;17(9):698–700.PubMedCrossRef

32.

Treglia G, Cason E, Stefanelli A, Cocciolillo F, di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22(1):43–55.PubMedCrossRef

33.

Chung EJ, Kim SJ. ¹²³I-metaiodobenzyl-guanidine myocardial scintigraphy in Lewy body-related disorders: a literature review. J Mov Disord. 2015;8(2):55–66.PubMedPubMedCentralCrossRef

34.

Catalan M, Dore F, Polverino P, Bertolotti C, Sartori A, Antonutti L, et al. ¹²³I-metaiodobenzylguanidine myocardial scintigraphy in discriminating degenerative parkinsonisms. Mov Disord Clin Pract. 2021;8(5):717–24.PubMedPubMedCentralCrossRef

35.

Shafie M, Mayeli M, Saeidi S, Mirsepassi Z, Abbasi M, Shafeghat M, et al. The potential role of the cardiac MIBG scan in differentiating the drug-induced Parkinsonism from Parkinson’s disease. Clin Park Relat Disord. 2022;6:100130.PubMedPubMedCentral

36.

Soman P, Travin MI, Gerson M, Cullom SJ, Thompson R. I-123 MIBG cardiac imaging. J Nucl Cardiol. 2015;22(4):677–85.PubMedCrossRef

37.

Vetrugno R, Liguori R, Cortelli P, Montagna P. Sympathetic skin response: basic mechanisms and clinical applications. Clin Auton Res. 2003;13(4):256–70.PubMedCrossRef

38.

Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1–8.PubMedPubMedCentralCrossRef

39.

Park JY, Yang D, Yang HJ, Kim HA, Kim S, Heo D, et al. Quantitative autonomic function test in differentiation of multiple system atrophy from idiopathic Parkinson disease. Chin Med J. 2019;132(16):1919–24.PubMedPubMedCentralCrossRef

40.

R Core Team. R: a language and environment for statistical computing. Vienna: Austria; 2021. https://www.R-project.org/

41.

Spiegel J. Diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson’s disease. Parkinsons Dis. 2010;2010:295346.PubMed

42.

Slaets S, van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ, et al. Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry. 2015;30(8):864–9.PubMedCrossRef

43.

Roberts G, Durcan R, Donaghy PC, Lawley S, Ciafone J, Hamilton CA, et al. Accuracy of cardiac innervation scintigraphy for mild cognitive impairment with Lewy bodies. Neurology. 2021;96(23):e2801–11.PubMedPubMedCentralCrossRef

44.

Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of ¹²³I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119(6):1329–37.PubMedCrossRef

45.

Wakasugi S, Inoue M, Tazawa S. Assessment of adrenergic neuron function altered with progression of heart failure. J Nucl Med. 1995;36(11):2069–74.PubMed

46.

Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol. 2008;15(3):442–55.PubMedCrossRef

47.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of ¹²³I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6(7):772–84.PubMedCrossRef

48.

Katagiri A, Asahina M, Araki N, Poudel A, Fujinuma Y, Yamanaka Y, et al. Myocardial ¹²³I-MIBG uptake and cardiovascular autonomic function in Parkinson’s disease. Parkinsons Dis. 2015;2015:805351.PubMedPubMedCentral

49.

Pérez T, Tijero B, Gabilondo I, Luna A, Llorens V, Berganzo K, et al. Cardiocirculatory manifestations in Parkinson’s disease patients without orthostatic hypotension. J Hum Hypertens. 2015;29(10):604–9.PubMedCrossRef

50.

Jeong YJ, Jeong JE, Cheon SM, Yoon BA, Kim JW, Kang DY. Relationship between the washout rate of I-123 MIBG scans and autonomic function in Parkinson’s disease. PLoS One. 2020;15(3):e0229860.PubMedPubMedCentralCrossRef

51.

Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum. 2016;22(2):435–63.PubMedPubMedCentral

Title: Optimal Protocol and Clinical Usefulness of 123I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases
Author: In Kook Chun
Publication date: 07-03-2023
Publisher: Springer Nature Singapore
Keywords: Dementia
Parkinson's Disease
Dementia
Scintigraphy
Atypical Parkinsonism
Progressive Supranuclear Palsy
Published in: Nuclear Medicine and Molecular Imaging / Issue 3/2023
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-023-00790-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Optimal Protocol and Clinical Usefulness of ¹²³I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients with Chronic Coronary Artery Disease

Diagnosis of Fungal Infection (Candida albicans) After Heart Transplantation in a Pediatric Case with Fever of Unknown Origin: Role of 99mTc-UBI SPECT/CT and 18F-FDG PET/CT

Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study

Hot Embolus Artifact Mimicking Disease Progression in Post-therapy 177Lu-DOTATATE Scan: Incremental Value of SPECT/CT

Tc-99 m Ubiquicidin Imaging in Orbital Aspergilloma: an Illustration

Dual-Tracer Parathyroid Imaging Using Joint SPECT Reconstruction